Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Next Previous
Trial Profile

A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Procedural pain
  • Focus Therapeutic Use
  • Sponsors Juniper Pharmaceuticals

Most Recent Events

  • 17 Aug 2016 Primary endpoint has not been met "Pain Intensity recorded on the 11-point NPRS" according to a Juniper Pharmaceuticals media release.
  • 17 Aug 2016 According to a Juniper Pharmaceuticals media release, the development of COL-1077 was discontinued based on the results of this study.
  • 04 Aug 2016 According to a Juniper Pharmaceuticals media release, the company anticipates to report top-line results from this trial by Sep 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top